ES2716681T3 - Proceso no mecánico para la micronización de digoxina - Google Patents
Proceso no mecánico para la micronización de digoxina Download PDFInfo
- Publication number
- ES2716681T3 ES2716681T3 ES15178009T ES15178009T ES2716681T3 ES 2716681 T3 ES2716681 T3 ES 2716681T3 ES 15178009 T ES15178009 T ES 15178009T ES 15178009 T ES15178009 T ES 15178009T ES 2716681 T3 ES2716681 T3 ES 2716681T3
- Authority
- ES
- Spain
- Prior art keywords
- digoxin
- mixture
- methanol
- solution
- concentrated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 title claims description 59
- 229960005156 digoxin Drugs 0.000 title claims description 59
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 title claims description 59
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 title claims description 59
- 238000010297 mechanical methods and process Methods 0.000 title description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 20
- 230000008569 process Effects 0.000 claims description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- 239000002244 precipitate Substances 0.000 claims description 13
- 239000003960 organic solvent Substances 0.000 claims description 8
- 239000007857 degradation product Substances 0.000 claims description 6
- 238000001556 precipitation Methods 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 239000002245 particle Substances 0.000 description 16
- 239000003814 drug Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 238000011282 treatment Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 240000001879 Digitalis lutea Species 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000005226 mechanical processes and functions Effects 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010003662 Atrial flutter Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 210000001992 atrioventricular node Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000036279 refractory period Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15178009.5A EP3120839B1 (en) | 2015-07-23 | 2015-07-23 | Non-mechanical process for the micronization of digoxin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2716681T3 true ES2716681T3 (es) | 2019-06-14 |
Family
ID=54010825
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15178009T Active ES2716681T3 (es) | 2015-07-23 | 2015-07-23 | Proceso no mecánico para la micronización de digoxina |
| ES16754316T Active ES2765675T3 (es) | 2015-07-23 | 2016-07-21 | Proceso no mecánico para la micronización de digoxina |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16754316T Active ES2765675T3 (es) | 2015-07-23 | 2016-07-21 | Proceso no mecánico para la micronización de digoxina |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180207099A1 (enExample) |
| EP (2) | EP3120839B1 (enExample) |
| JP (1) | JP6814522B2 (enExample) |
| KR (1) | KR20180032587A (enExample) |
| CN (1) | CN108024963A (enExample) |
| AU (1) | AU2016296162B2 (enExample) |
| ES (2) | ES2716681T3 (enExample) |
| HU (2) | HUE042420T2 (enExample) |
| MX (1) | MX365906B (enExample) |
| PL (2) | PL3120839T3 (enExample) |
| PT (2) | PT3120839T (enExample) |
| WO (1) | WO2017013485A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111110632B (zh) * | 2018-10-31 | 2023-01-20 | 上海上药信谊药厂有限公司 | 一种地高辛气雾剂及其制备方法和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3643760A1 (de) * | 1986-12-20 | 1988-06-23 | Boehringer Mannheim Gmbh | Verfahren zur anreicherung und/oder isolierung von herzglykosiden unter verwendung unpolarer adsorberharze |
| WO2003007968A1 (en) | 2001-07-17 | 2003-01-30 | Sun Pharmaceutical Industries Ltd. | A cardiotonic composition |
| CN101390838A (zh) * | 2008-10-10 | 2009-03-25 | 北京工业大学 | 一种制备微粉化药物的方法 |
-
2015
- 2015-07-23 EP EP15178009.5A patent/EP3120839B1/en active Active
- 2015-07-23 ES ES15178009T patent/ES2716681T3/es active Active
- 2015-07-23 HU HUE15178009A patent/HUE042420T2/hu unknown
- 2015-07-23 PT PT15178009T patent/PT3120839T/pt unknown
- 2015-07-23 PL PL15178009T patent/PL3120839T3/pl unknown
-
2016
- 2016-07-21 AU AU2016296162A patent/AU2016296162B2/en not_active Ceased
- 2016-07-21 JP JP2018503128A patent/JP6814522B2/ja not_active Expired - Fee Related
- 2016-07-21 ES ES16754316T patent/ES2765675T3/es active Active
- 2016-07-21 HU HUE16754316A patent/HUE048065T2/hu unknown
- 2016-07-21 US US15/746,697 patent/US20180207099A1/en not_active Abandoned
- 2016-07-21 CN CN201680042406.3A patent/CN108024963A/zh active Pending
- 2016-07-21 KR KR1020187003325A patent/KR20180032587A/ko not_active Ceased
- 2016-07-21 PT PT167543164T patent/PT3324942T/pt unknown
- 2016-07-21 EP EP16754316.4A patent/EP3324942B1/en active Active
- 2016-07-21 WO PCT/IB2016/001035 patent/WO2017013485A1/en not_active Ceased
- 2016-07-21 MX MX2018001010A patent/MX365906B/es active IP Right Grant
- 2016-07-21 PL PL16754316T patent/PL3324942T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018001010A (es) | 2018-05-17 |
| CN108024963A (zh) | 2018-05-11 |
| AU2016296162A1 (en) | 2018-02-01 |
| PL3120839T3 (pl) | 2019-08-30 |
| JP2018521073A (ja) | 2018-08-02 |
| HUE042420T2 (hu) | 2019-07-29 |
| PT3120839T (pt) | 2019-03-25 |
| BR112018001204A2 (pt) | 2018-09-11 |
| HUE048065T2 (hu) | 2020-05-28 |
| JP6814522B2 (ja) | 2021-01-20 |
| PL3324942T3 (pl) | 2020-05-18 |
| ES2765675T3 (es) | 2020-06-10 |
| MX365906B (es) | 2019-06-18 |
| US20180207099A1 (en) | 2018-07-26 |
| PT3324942T (pt) | 2020-01-17 |
| EP3120839B1 (en) | 2018-12-19 |
| EP3324942A1 (en) | 2018-05-30 |
| AU2016296162B2 (en) | 2021-03-18 |
| KR20180032587A (ko) | 2018-03-30 |
| WO2017013485A1 (en) | 2017-01-26 |
| EP3120839A1 (en) | 2017-01-25 |
| EP3324942B1 (en) | 2019-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI745349B (zh) | 一種含有ｊａｋ激酶抑制劑或其可藥用鹽的醫藥組成物 | |
| ES2326529T3 (es) | Composicion farmaceutica que contiene una forma amorfa estabilizada de clorhidrato de donepezil. | |
| JP2019509268A5 (enExample) | ||
| CN103880910A (zh) | 一种环黄芪醇的制备方法及其用途 | |
| CN104721181A (zh) | 二氢杨梅素在制备促进睡眠、改善睡眠质量制剂的用途 | |
| ES2716681T3 (es) | Proceso no mecánico para la micronización de digoxina | |
| CN101423537A (zh) | 灯盏乙素酯及其医疗用途 | |
| JP4863875B2 (ja) | ウチワサボテン植物の部分および／またはそれからの抽出物を含むうつ病治療剤 | |
| CN101756955B (zh) | 知母宁复合物及其制备方法和应用 | |
| CN101367799A (zh) | 苦参碱丹参酚酸b复盐和苦参素丹参酚酸b复盐及其制备方法和用途 | |
| WO2009123169A1 (ja) | アミド誘導体含有医薬組成物 | |
| CN108938580B (zh) | 盐酸帕罗西汀口崩片 | |
| CN107200769A (zh) | 一种具有防治肿瘤转移作用的救必应酸衍生物 | |
| BR112018001204B1 (pt) | Processo não-mecânico para a micronização da digoxina | |
| CN103830273B (zh) | 黄腐酸盐在制备促血管新生药物中的应用 | |
| WO2020064188A1 (en) | Pharmaceutical composition comprising solid dispersions of amorphous cladribine and pharmaceutically acceptable water-soluble carrier | |
| CN102068431B (zh) | 一种咔唑磺酰胺类抗肿瘤药物片剂及其制备方法 | |
| CN110818664B (zh) | 一种葛根素新型衍生物及其制备方法和用途 | |
| JP3935539B2 (ja) | フマル酸ケトチフェン含有医薬組成物 | |
| WO1997030706A1 (en) | Composition containing antitumor agent | |
| CN106581027B (zh) | 一种化合物及其药物用途、组合物与制剂 | |
| KR20140118410A (ko) | 저장 및 pH 안정성이 개선된 에페리손 의약 조성물 | |
| ES2645471T3 (es) | Derivados de hiperforina y su uso en la enfermedad de Alzheimer | |
| CN104147012A (zh) | 一种含有替加氟、吉莫斯特和奥替拉西钾的口腔崩解制剂 | |
| CN101455673A (zh) | 化合物肉桂基-(6＇-O-α-L-吡喃阿拉伯糖)-O-β-D-吡喃葡萄糖苷在制备抗抑郁药物中的应用 |